Archive for August 2020

SAWC Spotlight: Amniox Discusses Company Developments

Our primary goal is to be the industry leader in birth tissue regenerative medicine—driving our transition from a leader in the tissue space to an emerging biotech company.

How TissueTech Managed Growth, Virtual Trials, And Survived COVID-19

Since its inception in 1997, TissueTech has been a pioneer in the clinical application of human birth tissues. The company’s products have been used in more than 500,000 human transplants across multiple indications, under the regulatory classification of human cell and tissue products (HCT/Ps).

How Women Entrepreneurs Can Pitch Their Ideas With Great SuccessPitching an idea for a new venture is much more challenging if you’re a woman.

Amy Tseng heads up the biotech company TissueTech, which received $110 million in funding. Her background is in business and finance, and she has a keen eye for a profitable opportunity. She likes to keep R&D pipelines fully loaded to identify new markets for “leveraging our core technology.”

TissueTech to Collaborate with Johns Hopkins University-based Investigators

Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company involved in the research of the clinical application of human birth tissue-based products, announced today that Yun Guan, MD, PhD, professor of anesthesiology and critical care medicine, and professor of neurological surgery at the Johns Hopkins University School of Medicine, has been awarded a 5-year R01 grant […]